FDA Law Blog: FDA Prevails in Challenge Over Methylphenidate ANDA Rating Downgrade, But the Decision is Appealed; Meanwhile, the Agency Flip-Flops on Dexmethylphenidate Bioequivalence Requirements
SE ORDENA RETROTRAER LOS PRECIOS DE LA MEDICINA PREPAGA
Hace 11 horas
No hay comentarios:
Publicar un comentario